sharewise

3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium

As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

DexCom, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights - DXCM

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on ...

Patients with rarer types of diabetes can get up to 80% in subsidies for monitoring devices

Rarer diabetes patients in Singapore can now receive up to 80% government subsidies for continuous glucose monitoring (CGM) ...
Medscape

New Dexcom G7 Feature Cleared as 15-day Sensor Set to Launch

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
FierceBiotech

FDA clears Dexcom's Type 2 diabetes software for optimizing basal insulin doses

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors. The company said its Smart Basal ...
Morningstar

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the ...
The Motley Fool

DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Forbes

Is Dexcom Stock A Buy Now?

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...
Barron's

DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock.

Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
Benzinga.com

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
MobiHealthNews

Dexcom launches new titration module for basal insulin initiation

At the 61st annual European Association for the Study of Diabetes Conference (EASD) this week in Vienna, Austria, glucose monitoring company Dexcom introduced its new offering, the Dexcom Smart Basal, ...